Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy

  • Choli Hartono
  • , Miriam Chung
  • , Sheng F. Kuo
  • , Surya V. Seshan
  • , Thangamani Muthukumar

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The nephrotic syndrome due to idiopathic membranous nephropathy is often resistant to glucocorticosteroids and requires an alkylating agent such as chlorambucil or cyclophosphamide to induce remission. Recent studies illustrate that antibodies against the autoantigen M-type phospholipase A2 receptor contribute to a vast majority but not all cases of idiopathic membranous nephropathy. Herein, we report a patient with nephrotic syndrome due to membranous nephropathy that was resistant to 6 months of therapy with ramipril and high-dose glucocorticosteroids but responded to a single cycle of bortezomib infusion.

Original languageEnglish
Pages (from-to)103-106
Number of pages4
JournalJournal of Nephrology
Volume27
Issue number1
DOIs
StatePublished - Feb 2014
Externally publishedYes

Keywords

  • Bortezomib
  • Membranous nephropathy
  • Nephrotic syndrome
  • Proteasome inhibitor

Fingerprint

Dive into the research topics of 'Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy'. Together they form a unique fingerprint.

Cite this